Bei Jing Shang Bao·2025-11-21 00:00Core Viewpoint - The Chinese vaccine industry is facing intense price competition, leading to significant profit declines for many companies. The China Vaccine Industry Association has called for members to resist disorderly low-price competition and adhere to fair pricing practices to stabilize the market and promote innovation [1][2][3]. Group 1: Industry Challenges - The price war in the vaccine industry has intensified, with the price of the bivalent HPV vaccine dropping to as low as 27.5 yuan per dose, and flu vaccines reaching as low as 5.5 yuan per dose [4][6]. - In the first three quarters of this year, 71.43% of A-share vaccine companies reported a decline in net profit, with notable losses from companies like Wantai Biological Pharmacy and BCG Biological [6][7]. Group 2: Association's Initiative - The China Vaccine Industry Association has issued an initiative to promote high-quality development in the vaccine sector by advocating for self-discipline, innovation, and fair competition [2][3]. - The initiative emphasizes compliance with national laws and industry self-regulation, urging members to set prices based on production costs and market demand, while strictly prohibiting bidding below cost [2][3]. Group 3: Long-term Outlook - Experts believe that if the association's initiative is effectively implemented, it could lead to a more orderly competitive landscape, enhancing the industry's sustainability and improving vaccine safety and efficacy [3][7]. - The vaccine industry is seen as a crucial segment of the biopharmaceutical sector, with potential for growth as public health awareness and innovation capabilities improve [7].